CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue

Stock Information for Citius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Pharmaceuticals Inc.

CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai
CytoSorbents Rights Offering Begins
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.